Search clinical trials for: Maraviroc placebo

Total 54005 results

National Institute of Allergy and Infectious Diseases...

Completed

Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)

HIV Infections

United States, Puerto Rico, Thailand, South Africa, Brazil
International Partnership for Microbicides, Inc.

Withdrawn

A Safety and Pharmacokinetic Study for Dapivirine and Maraviroc Gel in Belgium

HIV Infections
University of California, San Francisco
Pfizer; Stanford University; amfAR, The Foundation for AIDS Research; Case Western... and other collaborators

Completed

Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure

HIV Infection

United States
International Partnership for Microbicides, Inc.

Completed

Safety and Pharmacokinetics of Dapivirine/Maraviroc Vaginal Ring

HIV Infections

United States
ANRS, Emerging Infectious Diseases
Pfizer

Completed

Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients (OPTIMAL)

HIV-1 Infection | AIDS

France
Abramson Cancer Center of the University of Pennsylvania

Completed

Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation

Hematopoietic Stem Cell Transplantation | Graft-versus-host Disease
ViiV Healthcare
Pfizer

Completed

Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects

Healthy

Belgium
ViiV Healthcare
Pfizer

No longer available

A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India

Human Immunodeficiency Virus (HIV)
S.F.L. van Lelyveld
Pfizer; Erasmus Medical Center; Academisch Medisch Centrum - Universiteit van... and other collaborators

Completed

Maraviroc Immune Recovery Study (MIRS)

HIV Infections

Netherlands
Schülke & Mayr GmbH

Terminated

Study to Evaluate the Efficacy of Octenisept® in Patients With Chronic Wounds

Ulcus Cruris

Germany
National Institute of Allergy and Infectious Diseases...
AIDS Clinical Trials Group; HIV Prevention Trials Network

Completed

Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women

HIV Infection

United States, Puerto Rico
ViiV Healthcare
Pfizer

Completed

Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus

HIV

United States, United Kingdom, Germany
ViiV Healthcare
Pfizer

Completed

Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus

HIV Infections

Netherlands, Germany, United Kingdom
Kirby Institute

Completed

MARCH Vascular Endothelium Substudy (MARCH VE)

Cardiovascular Disease

Argentina, Australia, Germany, Thailand
ViiV Healthcare
Pfizer

Completed

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects (MOTIVATE 1)

HIV Infections

United States, Canada
Pfizer

Terminated

Maraviroc in Rheumatoid Arthritis

Arthritis, Rheumatoid

United States, Spain, Italy, Portugal, Germany, India, Australia, Ukraine, Mexico
International Partnership for Microbicides, Inc.
National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...

Completed

Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative Adults

HIV/AIDS

United States
St Stephens Aids Trust

Completed

A Study to Assess Cerebrospinal Fluid INflammatory Markers After Addition of Maraviroc to MONotherapy Darunavir/Ritonavir - The CINAMMON Study (CINAMMON)

HIV

United Kingdom
University of Maryland, Baltimore
Merck Sharp & Dohme LLC

Completed

R5 Integrase Study in HIV-1 Naive Patients

HIV Infections

United States
Emory University

Completed

Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women (MVC-PREP)

HIV

United States
French National Agency for Research on AIDS and...
Pfizer

Completed

Evaluation of Maraviroc Intensification in HIV Infected Patients With Insufficient Immune Restoration (145 MARIMUNO)

HIV Infections | HIV Infection

France
University Of Perugia

Completed

Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients.

Inflammation | Atherosclerosis | Cardiovascular Risk Factor | HIV Infection With Other Conditions

Italy
Germans Trias i Pujol Hospital

Completed

Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects

HIV Infections | HIV

Spain
ViiV Healthcare
Pfizer

Completed

Prospective Observational Epidemiologic Study of Maraviroc's Safety (POEM)

Human Immunodeficiency Virus

United States, Canada, Spain, Belgium, France, United Kingdom, Italy, Brazil, Puerto Rico, Germany, Greece
ViiV Healthcare

Completed

Expanded Access Program for Maraviroc At Multiple Centers

HIV Infections

Canada, United States, Spain, Switzerland, Malaysia, France, Italy, Portugal, Puerto Rico, Mexico, Australia, Ireland, Romania, Greece, United Kingdom, Argentina, Austria, Belgium, Chile, Costa Rica, Dominican Republic, Germany, Hong... and more
University of California, Los Angeles

Terminated

Maraviroc to Augment Rehabilitation Outcomes After Stroke (MAROS)

Stroke

United States
ViiV Healthcare
Pfizer

Completed

Non-Interventional Study Of Celsentri® In Treatment Experienced Patients With CCR5-Tropic HIV-Infection

HIV-1
Centre hospitalier de l'Université de Montréal...
McGill University Health Centre/Research Institute of the McGill University... and other collaborators

Completed

The Effects of the Direct Acting Antiviral Agent Boceprevir on the Pharmacokinetics of Maraviroc in Healthy Volunteers

Healthy

Canada
Fundación Pública Andaluza para la gestión de la...

Completed

Trial to Evaluate the Safety and Efficacy of Maraviroc in Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) (COVIMAR)

Virus Diseases

Spain
University of Hawaii
Pfizer

Completed

Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels

HIV Infections

United States
Asociacion para el Estudio de las Enfermedades...

Completed

Double-method Comparative Study in Order to Predict the Use of Co-receptors From Type 1 HIV: Phenotypic Study (Trofile ESTA®) and Virologic Response to a CCR5 Antagonist in the Short Term (TROPISMVC)

HIV Infections

Spain
ViiV Healthcare
Pfizer

Completed

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects (MOTIVATE 2)

HIV Infections

Netherlands, United States, Italy, Spain, United Kingdom, France, Germany, Australia, Switzerland, Belgium, Canada, Poland, Sweden
Hospital Universitario Infanta Leonor
Hospital Clinic of Barcelona; ViiV Healthcare

Terminated

Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19). (MARACOVID)

COVID-19

Spain
Tel-Aviv Sourasky Medical Center

Completed

Safety of Maraviroc for Post-stroke Depression (MRV-PSD)

Post-stroke Depression

Israel
ViiV Healthcare
Pfizer; Copenhagen HIV Programme

Completed

EuroSIDA As An External Comparator To MOTIVATE Trials

HIV | AIDS
ViiV Healthcare
Pfizer

Completed

Investigation Of Safety And Pharmacokinetics Following A Single Oral Dose Of 300 Mg Maraviroc In Healthy Male Japanese Volunteers

Human Immunodeficiency Virus (HIV) Infection

Singapore
ViiV Healthcare
Pfizer

Terminated

Multicenter Pilot Study To Define The Marker As An Alternate For Tropism Assay

HIV Infections

United States, Canada
Kevin F. Gibson
University of Pittsburgh

Terminated

Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes (GRADS)

Sarcoidosis

United States
ViiV Healthcare
Pfizer

Completed

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects

HIV Infections

Canada, United States, United Kingdom, Netherlands, Australia, Germany, Spain, Belgium, Switzerland
ViiV Healthcare
Pfizer

Completed

Safety And Efficacy Of Maraviroc In Patients For HIV Patients (Regulatory Post Marketing Commitment Plan)

CCR5-tropic HIV-1 Infection
ASST Fatebenefratelli Sacco

Completed

Maraviroc in Immunological Non-Responder (INR) HIV-1-infected Subjects

HIV Infections

Italy
Temple University
Pfizer; Abbott

Terminated

Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study) (KALMAR)

HIV Infections

United States
ViiV Healthcare
Pfizer

Completed

A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

Human Immunodeficiency Virus-1

United States, Spain, Germany
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC; ViiV Healthcare

Terminated

Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy (ROCnRAL)

Human Immunodeficiency Virus | Lipohypertrophy

France
University of California, San Francisco
National Heart, Lung, and Blood Institute (NHLBI); Pfizer

Completed

Effect of Maraviroc on Endothelial Function in HIV-Infected Patients

HIV Infections | HIV Infection | Inflammation | Cardiovascular Disease

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Phase II Maraviroc for GVHD Prevention

Hematologic Malignancy

United States
Fundacion para la Investigacion Biomedica del Hospital...
Pfizer

Completed

Effect Of A CCR5 Coreceptor Antagonist On The Latency And Reservoir Of HIV-1

HIV-1

Spain
Hospital General de México Dr. Eduardo Liceaga
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran; CCINSHAE... and other collaborators

Terminated

Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults (COMVIVIR)

COVID-19

Mexico
ViiV Healthcare
Pfizer

Completed

THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC

Healthy Subjects

United States
St Stephens Aids Trust

Terminated

Impact of Maraviroc on the Immune Function in HIV-1 Infected Subjects Receiving Immunisation With Novel Antigens

HIV Infections

United Kingdom

Search clinical trials for: Maraviroc placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations